BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19860669)

  • 1. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.
    Pasero C; Truneh A; Olive D
    Curr Mol Med; 2009 Sep; 9(7):911-27. PubMed ID: 19860669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.
    Steinberg MW; Cheung TC; Ware CF
    Immunol Rev; 2011 Nov; 244(1):169-87. PubMed ID: 22017438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
    Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
    del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
    J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
    Pasero C; Speiser DE; Derré L; Olive D
    Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.
    Ware CF
    Immunol Rev; 2008 Jun; 223():186-201. PubMed ID: 18613837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.
    Cheung TC; Humphreys IR; Potter KG; Norris PS; Shumway HM; Tran BR; Patterson G; Jean-Jacques R; Yoon M; Spear PG; Murphy KM; Lurain NS; Benedict CA; Ware CF
    Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13218-23. PubMed ID: 16131544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
    Murphy TL; Murphy KM
    Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.
    Granger SW; Rickert S
    Cytokine Growth Factor Rev; 2003; 14(3-4):289-96. PubMed ID: 12787566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
    Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model.
    Pierer M; Schulz A; Rossol M; Kendzia E; Kyburz D; Haentzschel H; Baerwald C; Wagner U
    J Immunol; 2009 Mar; 182(5):3139-45. PubMed ID: 19234211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing co-stimulation and inhibition with BTLA and HVEM.
    Murphy KM; Nelson CA; Sedý JR
    Nat Rev Immunol; 2006 Sep; 6(9):671-81. PubMed ID: 16932752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the LIGHT-HVEM pathway.
    Ware CF
    Adv Exp Med Biol; 2009; 647():146-55. PubMed ID: 19760072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.
    Pasero C; Barbarat B; Just-Landi S; Bernard A; Aurran-Schleinitz T; Rey J; Eldering E; Truneh A; Costello RT; Olive D
    Eur J Immunol; 2009 Sep; 39(9):2502-14. PubMed ID: 19701890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.
    Chang YH; Hsieh SL; Chao Y; Chou YC; Lin WW
    J Biomed Sci; 2005; 12(2):363-75. PubMed ID: 15917993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
    Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
    J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.